Eur Rev Med Pharmacol Sci 2018; 22 (14): 4458-4466
DOI: 10.26355/eurrev_201807_15497

KEAP1/NRF2 signaling pathway mutations in cervical cancer

X.-Y. Chu, Z.-J. Li, Z.-W. Zheng, Y.-L. Tao, F.-X. Zou, X.-F. Yang

Department of Gynecological Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, China. xiaoli0775@sina.com


OBJECTIVE: The aim of the present study was to explore the potential involvement of mutations in the KEAP1/NRF2 signaling pathway in Chinese samples with cervical cancer.

PATIENTS AND METHODS: 236 Chinese patients with various types of cervical cancer were recruited, and the coding exons and the corresponding intron-exon boundaries of the KEAP1 and NRF2 genes were analyzed for the potential mutations in the KEAP1/NRF2 signaling pathway.

RESULTS: A novel KEAP1 missense somatic mutation (c.1408C>T, p.R470C) and 5 NRF2 missense somatic mutations (c.72G>C, p.W24C; c.85G>T, p.D29Y; c.101G>A, p.R34Q; c.230A>C, p.D77A and c.242G>A p.G81D) were identified in 187 patients with cervical squamous cell carcinoma, respectively; no mutations were detected in other subtypes. All these mutations were heterozygous and predicted to be pathogenic by PolyPhen-2, MutationTaster programs, and evolutionary conservation analysis. Among these mutations, the KEAP1 (p.R470C) and 3 NRF2 mutations (p.D29Y, p.D77A, and p.G81D) were detected in cervical cancer for the first time. Also, no mutations were identified in our 21 adenosquamous carcinomas or 25 adenocarcinomas.

CONCLUSIONS: We identified 6 potential diseases causing mutations in the KEAP1/NRF2 signaling pathway in 187 (3.2%) Chinese cases with cervical squamous cell carcinoma, implicating KEAP1/NRF2 signaling pathway might play an active role in the pathogenesis of this subtype of cervical cancer. Furthermore, among these detected mutations, the KEAP1 and 3 NRF2 mutations were reported in cervical cancer for the first time.

Free PDF Download

To cite this article

X.-Y. Chu, Z.-J. Li, Z.-W. Zheng, Y.-L. Tao, F.-X. Zou, X.-F. Yang
KEAP1/NRF2 signaling pathway mutations in cervical cancer

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 14
Pages: 4458-4466
DOI: 10.26355/eurrev_201807_15497